All terms in ADO

Label Id Description
cellular_component GO_0005575 [A location, relative to cellular compartments and structures, occupied by a macromolecular machine when it carries out a molecular function. There are two ways in which the gene ontology describes locations of gene products: (1) relative to cellular structures (e.g., cytoplasmic side of plasma membrane) or compartments (e.g., mitochondrion), and (2) the stable macromolecular complexes of which they are parts (e.g., the ribosome).]
superoxide CHEBI_18421
PRIM1 OGG_3000005557
EPHA1 OGG_3000002041
hydrogen peroxide CHEBI_16240 [An inorganic peroxide consisting of two hydroxy groups joined by a covalent oxygen-oxygen single bond.]
organofluorine compound CHEBI_37143 [An organofluorine compound is a compound containing at least one carbon-fluorine bond.]
fluorine molecular entity CHEBI_24062
magnesium(2+) CHEBI_18420
impulsive behavior NBO_0000119 ["A behavior that occur quickly without control, planning, or consideration of the consequences of that behavior." [NBO:GVG]]
CLU OGG_3000001191
phospholipid CHEBI_16247 [A lipid containing phosphoric acid as a mono- or di-ester. The term encompasses phosphatidic acids and phosphoglycerides.]
phosphate CHEBI_26020 [Salts and esters of phosphoric and oligophosphoric acids and their chalcogen analogues. In inorganic chemistry, the term is also used to describe anionic coordination entities with phosphorus as central atom.]
niacin TXPO_0005150
object BFO_0000030
dephosphorylation GO_0016311 [The process of removing one or more phosphoric (ester or anhydride) residues from a molecule.]
phosphorylation GO_0016310 [The process of introducing a phosphate group into a molecule, usually with the formation of a phosphoric ester, a phosphoric anhydride or a phosphoric amide.]
PCDH11X OGG_3000027328
clinical trial phase CTO_0000201 [The quality of a clinical trial that studies a drug or biological product. The phase is based on the study's objective, the number of participants, and other characteristics. According to USA FDA, there are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4.]
Latrepirdine NCIT_C78757
enzyme inhibitor agent therapy MAXO_0000648 [A therapy using a compound or agent that combines with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.]